Bullfrog AI Holdings, Inc. (BFRG) stock analysis

Healthcare · Health Information Services

From the 10-K filed 2026-03-19

How it makes money

Collaborators and internal projects pay for the bfLEAP™ platform to improve drug development success.

Biopharmaceutical partners pay for the platform because it helps them synthesize complex data.

Increasing the probability of clinical trial success drives the value by reducing the high cost of developing new therapeutics.

What protects it: the moat

The company's platform relies on an exclusive, worldwide license from JHU-APL.

The bfLEAP™ platform technology is derived from work at The Johns Hopkins University Applied Physics Laboratory.

The company holds an exclusive, royalty-bearing license that includes patents and trade secrets.

What growth costs

The company must fund clinical and research initiatives to sustain its operations.

To execute its business plan, the company must invest in research, development, and clinical and regulatory efforts.

What could damage it

Inability to raise capital could stop the clinical research necessary for earnings.

The company currently faces significant losses and expects its existing cash will not fund operations for at least a year.

A failure to secure new funding would force the company to cut R&D and clinical efforts, preventing the realization of its business plan.

About Bullfrog AI Holdings, Inc.

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Other companies in Health Information Services